A Preclinical Overview of Ebastine
- Dr David J. Roberts
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Ebastine is a novel histamine H1 receptor antagonist that combines potency with a rapid onset (fast absorption) and long duration (slow elimination) of action, at least partially mediated via the formation of an acid metabolite (carebastine) that is even more potent as an antihistamine. It shows clear selectivity for histamine H1 as opposed to H2 receptors, has moderate activity against other potential mediators of allergic phenomena such as leukotriene C4 and platelet-activating factor, and is clearly effective against anaphylactic reactions resulting from exposure of suitably sensitised tissues or animals to antigen.
By contrast, ebastine has negligible activity against acetylcholine (no atropine-like adverse effects on secretions and visual accommodation) and only poorly penetrates the blood-brain barrier (no sedative adverse effects).
Ebastine is without effects on the central nervous and cardiovascular systems, even after oral administration of high doses, and does not interact pharmacologically with a wide range of other drugs covering most areas of potential coadministration. Furthermore, ebastine showed no clinically relevant effects in a complete set of regulatory-required toxicity tests (including acute, chronic, reproductive, mutagenic and carcinogenic protocols) at doses giving blood concentrations representing high multiples of clinical exposure.
In conclusion, ebastine has a preclinical profile indicative of an excellent therapeutic ratio of desired effects to undesired effects.
- Roberts DJ. Fifty years of antihistamine research — from phenbenzamine (RP 2339) to ebastine (RP 64305). Drugs Today 1992; 28 Suppl. B: 1–9.
- Dale HH. Croonian lectures on ‘some chemical factors in the control of the circulation’. Lancet 1929; 1: 1179–83, 1233–37, 1285–90.
- Llupia J, Bou J, Fernandez AG, et al. Antihistamine, anti-allergic and related pharmacological properties of ebastine, a new selective antihistamine H1-receptor antagonist. Drugs Today 1992; 28 Suppl. B: 11–21.
- Berga P, Puig J, Fernandez AG, et al. Preclinical safety studies with ebastine. I. Pharmacological effects on the central nervous system. Drugs Today 1992; 28 Suppl. B: 23–7.
- Llenas J, Bou J, Massingham R. Preclinical safety studies with ebastine. II. Pharmacological effects on the cardiovascular system. Drugs Today 1992; 28 Suppl. B: 29–34.
- Data on file, Laboratorios Almirall.
- Berga P, Llenas J, Llupia J, et al. Preclinical safety studies with ebastine. III. Drug interactions. Drugs Today 1992; 28 Suppl. B: 35–44.
- Martinez-Tobed A, Tarrus E, Segura J, et al. Pharmacokinetic studies in rats, dogs and man. Drugs Today 1992; 28 Suppl. B: 57–67.
- Jauregui J, Roberts DJ. Preclinical safety studies with ebastine. IV. Acute, chronic and reproductive toxicity, mutagenicity and carcinogenicity. Drugs Today 1992; 28 Suppl. B: 45–56.
- A Preclinical Overview of Ebastine
Volume 52, Issue 1 Supplement, pp 8-14
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Laboratorios Almirall, S.A., Cardener, 68-74, 08024, Barcelona, Spain